Clinical trial
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic…
NCT00301418 · Northwell Health, Other · Completed
Key facts
| NCT number | NCT00301418 |
|---|---|
| Title | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma |
| Official title | Phase I/II Trial of Oral Erlotinib (Tarceva, OSI-774) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma |
| Lead sponsor | Northwell Health, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma Multiforme, Anaplastic Astrocytoma |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 11 |
| Start date | Mar 1, 2006 |
| Primary completion | May 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Mar 10, 2006 |
| Last update posted | Feb 10, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: